Literature DB >> 11104225

Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?

D Dressler1, U Zettl, R Benecke, H Bigalke.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11104225     DOI： 10.1002/1531-8257(200011)15:6<1279::aid-mds1040>3.0.co;2-4

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  4 in total

1.  Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity.

Authors:  Dirk Dressler; Lizhen Pan; Fereshte Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2018-07-31       Impact factor: 3.575

Review 2.  [Antibody-induced failure of botulinum toxin therapy].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2003-12       Impact factor: 1.214

Review 3.  Immunogenicity Associated with Botulinum Toxin Treatment.

Authors:  Steven Bellows; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2019-08-26       Impact factor: 4.546

4.  Immunogenicity of botulinum toxin.

Authors:  Syeo Young Wee; Eun Soo Park
Journal:  Arch Plast Surg       Date:  2022-01-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.